Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secon...

Bibliografske podrobnosti
Main Authors:	Cavenaugh, J, Awi, D, Mendy, M, Hill, A, Whittle, H, McConkey, S
Format:	Journal article
Jezik:	English
Izdano:	Public Library of Science 2011

Podobne knjige/članki

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
od: James S Cavenaugh, et al.
Izdano: (2011-02-01)

Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.
od: McConkey, S, et al.
Izdano: (2004)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
od: McConkey, S, et al.
Izdano: (2003)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
od: Gilbert, S, et al.
Izdano: (2006)

Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians
od: Mendy, M, et al.
Izdano: (2006)

Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia
od: Waight Pauline A, et al.
Izdano: (2006-04-01)

DNA/MVA Vaccines for HIV/AIDS
od: Smita S. Iyer, et al.
Izdano: (2014-02-01)

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia
od: Crozier Sarah, et al.
Izdano: (2008-04-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
od: Hanke, T, et al.
Izdano: (2002)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
od: Moorthy, V, et al.
Izdano: (2004)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
od: Vasee S Moorthy, et al.
Izdano: (2004-11-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
od: De Barra, E, et al.
Izdano: (2014)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
od: Ye Zheng, et al.
Izdano: (2022-01-01)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis
od: Ryckman, K, et al.
Izdano: (2010)

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
od: Tamara Kusay Jabbar, et al.
Izdano: (2013-01-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
od: Lynette Siv Chea, et al.
Izdano: (2017-10-01)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
od: Joan Kha-Tu Ho, et al.
Izdano: (2020-01-01)

Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy
od: Scognamiglio Paola, et al.
Izdano: (2009-06-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians
od: Yindom, L, et al.
Izdano: (2017)

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine
od: Yu-Min Choi, et al.
Izdano: (2023-06-01)

Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.
od: Mendy, M, et al.
Izdano: (2010)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
od: Rollier, C, et al.
Izdano: (2016)

Therapeutic vaccines in HBV: lessons from HCV
od: Barnes, E
Izdano: (2015)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis.
od: Kelli K Ryckman, et al.
Izdano: (2010-08-01)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
od: Eoghan de Barra, et al.
Izdano: (2014-01-01)

Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus.
od: Mendy, M, et al.
Izdano: (2008)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
od: Wyatt LS, et al.
Izdano: (2009-10-01)

Correction: Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis.
od: Kelli K. Ryckman, et al.
Izdano: (2011-01-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
od: Louis-Marie Yindom, et al.
Izdano: (2017-01-01)

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model
od: Dorien De Pooter, et al.
Izdano: (2024-02-01)

Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-naïve chronic hepatitis B virus infection
od: Kun-yan Hao, et al.
Izdano: (2025-01-01)

Quantification of hepatitis B virus (HBV) DNA and HBV genotyping simultaneously in plasma using real-time polymerase chain reaction
od: Woottichai Khamduang, et al.
Izdano: (2018-08-01)

Virological profiles of hepatitis B virus (HBV)-infected African patients treated with tenofovir
od: H.F. Njai, et al.
Izdano: (2014-04-01)

A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review
od: Mokaya, J, et al.
Izdano: (2018)

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
od: Qiyao Wei, et al.
Izdano: (2025-02-01)

Mechanisms of Hepatitis B Virus cccDNA and Minichromosome Formation and HBV Gene Transcription
od: Andoni Gómez-Moreno, et al.
Izdano: (2024-04-01)

Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program
od: Peto, T, et al.
Izdano: (2014)

Generation of multivalent recombinant MVA vaccines for malaria
od: Orubu, T
Izdano: (2012)

The impact of hepatitis B virus (HBV) splicing on HBV replication and disease progression
od: Laura C. McCoullough, et al.
Izdano: (2024-08-01)

Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine
od: Horng-Jyh Tsai
Izdano: (2015-04-01)